IQVIA Holdings Inc. (NYSE:IQV) Given Consensus Rating of “Moderate Buy” by Brokerages

IQVIA Holdings Inc. (NYSE:IQV) has earned a consensus recommendation of “Moderate Buy” from the twenty-one research firms that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $249.1875.

Several equities research analysts recently issued reports on IQV shares. Baird R W raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 29th. BMO Capital Markets began coverage on shares of IQVIA in a research report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price target for the company. Barclays set a $230.00 price objective on shares of IQVIA in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. Finally, Evercore ISI raised their price target on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Institutional investors and hedge funds have recently modified their holdings of the stock. Verdence Capital Advisors LLC purchased a new position in shares of IQVIA during the 2nd quarter valued at about $3,612,000. Amundi raised its position in IQVIA by 46.3% during the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after acquiring an additional 405,250 shares in the last quarter. Act Two Investors LLC acquired a new position in IQVIA in the second quarter valued at approximately $26,528,000. Diversified Trust Co boosted its position in IQVIA by 57.2% in the 3rd quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock worth $8,087,000 after purchasing an additional 15,487 shares in the last quarter. Finally, Patton Fund Management Inc. acquired a new stake in shares of IQVIA during the 2nd quarter worth approximately $231,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 0.2%

NYSE:IQV opened at $242.70 on Friday. IQVIA has a one year low of $134.65 and a one year high of $247.05. The business has a fifty day moving average price of $224.37 and a 200-day moving average price of $200.48. The firm has a market capitalization of $41.33 billion, a price-to-earnings ratio of 33.29, a price-to-earnings-growth ratio of 2.47 and a beta of 1.36. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.IQVIA’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts forecast that IQVIA will post 10.84 EPS for the current year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.